Managing Director Service AgreementManaging Director Service Agreement • February 1st, 2021 • Eyegate Pharmaceuticals Inc • Pharmaceutical preparations
The managing director is a founding shareholder of Panoptes and has represented the company independently since 19 July 2013. He was appointed as managing director in the articles of association for the duration of his position as shareholder.
EYEGATE PHARMACEUTICALS, INC. FOURTH AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • February 1st, 2021 • Eyegate Pharmaceuticals Inc • Pharmaceutical preparations • Massachusetts
THIS FOURTH AMENDED AND RESTATED EMPLOYMENT AGREEMENT, entered into as of January 29, 2021 (this “Agreement”), is made by and between EyeGate Pharmaceuticals, Inc., a Delaware corporation (the “Employer”), and Stephen From the “Employee”).
1st Amendment of the Managing Director Service AgreementManaging Director Service Agreement • February 1st, 2021 • Eyegate Pharmaceuticals Inc • Pharmaceutical preparations
The Managing Director is employed on the basis of the Managing Director-Service Agreement dated December 18, 2020, entered into between him and the Company, represented by the CEO of the Company's sole shareholder EyeGate Pharmaceuticals, Inc ("EyeGate").
